Results 41 to 50 of about 5,184 (154)

Nirmatrelvir-ritonavir for COVID-19 [PDF]

Canadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources

Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions

Infectious Diseases and Therapy
Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph, Farid L. Khan, Tanya G. Singh, Srinivas Rao Valluri, Laura A. Puzniak, John M. McLaughlin   +5 more
doaj   +1 more source

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]

Osong Public Health and Research Perspectives
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim   +7 more
doaj   +1 more source

Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19

SAGE Open Medical Case Reports, 2023
COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure.
Elizabeth DeMarco, Matthew Turnipseed, Brian Clarke, Farhan Qadeer   +3 more
doaj   +1 more source

ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants

Journal of Medical Virology, Volume 98, Issue 7, July 2026.
ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández, Karen L. Reyes‐Barrera, Sergio N. Hidalgo‐Figueroa, Edgar D. Páez‐Pérez, Clara I. Espitia Pinzón, Ángel G. Alpuche‐Solís   +5 more
wiley   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj  

A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT COVID‐19 continues to be a threat to global health and a burden on healthcare systems. There is an ongoing need for COVID‐19 antiviral therapies that are safe and effective across broad patient populations. Ibuzatrelvir is a potent, selective inhibitor of the SARS‐CoV‐2 main protease and demonstrated favorable properties for clinical ...
Ravi Shankar P. Singh, Sima S. Toussi, Frances Hackman, Mona Shahbazi, John Prybylski, Siddhee A. Sahasrabudhe, Penelope Crownover, Eugene P. Kadar, Billy T. George, Negar Niki Alami, Arthur Bergman   +10 more
wiley   +1 more source

“Nirmatrelvir/ritonavir as a posible treatment for Long-COVID ”

, 2023
It is estimated that about 10% of patients who have been infected with SARS-CoV-2 worldwide suffer from Long-Covid, about 65 million people [1]. Although we are beginning to know its pathophysiology, there is still no evidence on its treatment.
Ignacio Pérez Catalán, Adriana Gascon Buj, Sergio García Muñoz, Iris Gómez Alfaro, Celia Roig Martí, Miguel Torres García, Roberto Reig Valero, Raúl Ferrando Piqueres, Lidón Mateu Campos, Jose-Manuel Ramos, Jorge Usó Blasco   +10 more
openaire   +2 more sources

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild‐to‐Moderate COVID‐19 Cases in a Broadly Immune Population

Medical Journal of Australia, Volume 224, Issue 7, July 2026.
ABSTRACT Antivirals for mild‐to‐moderate coronavirus disease 2019 (COVID‐19) were adopted for use based on trials in unvaccinated adults during the pre‐Omicron period. In today's broadly immune populations, where the risk of hospitalisation and death has decreased substantially, there is a lack of high‐quality contemporary evidence to support routine ...
Hadar Mudrik‐Zohar, Tim Cutfield, Susan Morpeth, Thomas Hills, Eamon Duffy, Laura J. Edwards, Allen C. Cheng, Steven Y. C. Tong   +7 more
wiley   +1 more source